Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Net Income (2017 - 2025)

Historic Net Income for Lexaria Bioscience (LEXX) over the last 12 years, with Q4 2025 value amounting to -$1.6 million.

  • Lexaria Bioscience's Net Income rose 4144.97% to -$1.6 million in Q4 2025 from the same period last year, while for Nov 2025 it was -$10.8 million, marking a year-over-year decrease of 4747.72%. This contributed to the annual value of -$11.9 million for FY2025, which is 10697.15% down from last year.
  • As of Q4 2025, Lexaria Bioscience's Net Income stood at -$1.6 million, which was up 4144.97% from -$2.7 million recorded in Q3 2025.
  • Lexaria Bioscience's Net Income's 5-year high stood at -$25000.0 during Q1 2021, with a 5-year trough of -$3.8 million in Q2 2025.
  • Its 5-year average for Net Income is -$1.8 million, with a median of -$1.7 million in 2022.
  • Per our database at Business Quant, Lexaria Bioscience's Net Income tumbled by 6688273.33% in 2021 and then surged by 4953.21% in 2024.
  • Over the past 5 years, Lexaria Bioscience's Net Income (Quarter) stood at -$2.0 million in 2021, then grew by 15.38% to -$1.7 million in 2022, then surged by 33.24% to -$1.1 million in 2023, then crashed by 137.73% to -$2.7 million in 2024, then surged by 41.45% to -$1.6 million in 2025.
  • Its Net Income was -$1.6 million in Q4 2025, compared to -$2.7 million in Q3 2025 and -$3.8 million in Q2 2025.